13F Holdings
中文EN

VERA Vera Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1831828 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-64.8%
TTM EPS YoY-47.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-113.5%
ROA-84.5%
ROIC (approx.)-87.8%
Asset turnover—

Leverage & solvency

Liabilities / assets28.5%
Debt / equity0.23x
Current ratio7.91x
Interest coverage-57.40x

Cash quality & payout

Operating cash flow / net income0.91x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$215.26M$126.17M$78.22M$68.99M$22.48M
SG&A expense$100.22M$41.00M$23.79M$21.91M$11.92M
Operating income-$315.47M-$167.17M-$102.01M-$90.90M-$34.40M
Interest expense$7.53M$7.63M$3.79M$992,000$20,000
Pretax income-$299.61M-$152.15M-$95.99M-$89.06M-$32.61M
Income tax$1,000$1,000$1,000$1,000$1,000
Net income-$299.62M-$152.15M-$95.99M-$89.06M-$32.61M
EBITDA-$315.00M-$167.06M-$101.99M-$91.75M-$34.23M
EPS (basic)-4.66-2.75-2.25-3.35-2.43
EPS (diluted)-4.66-2.75-2.25-3.35-2.43
Weighted avg. shares (diluted)64.23M55.33M42.71M26.57M13.44M
Balance sheet
Cash & equivalents$354.73M$92.65M$45.68M$43.75M$79.97M
Short-term investments$359.86M$548.21M$115.03M$71.19M$0
Receivables$0————
Inventory$0————
Current assets$728.88M$651.22M$172.02M$125.70M$82.54M
PP&E, net$1.37M$960,000$92,000$51,000$0
Intangibles$0————
Total assets$734.73M$655.68M$175.55M$131.44M$83.75M
Current liabilities$53.45M$25.37M$22.30M$25.60M$7.69M
Long-term debt$74.84M$50.69M$49.88M$24.81M$4.92M
Total debt$74.84M$50.69M$49.88M$24.81M$4.92M
Total liabilities$130.21M$78.53M$73.86M$54.53M$14.16M
Shareholders' equity$604.52M$577.15M$101.69M$76.91M$69.59M
Net debt-$279.89M-$41.96M$4.20M-$18.94M-$75.04M
Cash flow statement
Operating cash flow-$241.10M-$134.68M-$92.18M-$67.60M-$23.71M
Capital expenditure$630,000$972,000$63,000$62,000$0
Free cash flow-$241.73M-$135.65M-$92.24M-$67.66M-$23.71M
Investing cash flow$194.29M-$425.03M-$39.43M-$70.55M-$4.20M
Financing cash flow$308.90M$606.67M$133.54M$101.93M$53.88M
Depreciation & amortization$468,000$105,000$21,000-$846,000$176,000
Stock-based compensation$37.93M$20.80M$11.49M$8.89M$3.01M
Share buybacks$0$13,000$0——

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.